Eph2A Inhibitors
1 drugsAbout Eph2A
Eph receptor A2 (Eph2A) is a receptor tyrosine kinase involved in cell communication, influencing cell migration, adhesion, and differentiation. Activated by ephrin ligands, it triggers downstream signaling cascades that regulate fundamental cellular processes.
Currently, there is no genetic evidence directly linking Eph2A to specific diseases, limiting confidence in target validation. However, its role in key cellular processes makes it a potential target for drug development.
Eph2A is targeted by one FDA-approved drug, STIVARGA (Bayer), a small molecule with three indications. This single drug highlights the potential, yet limited, therapeutic focus on this receptor.
Top Eph2A Drugs
Bayer is the only company with an approved drug targeting Eph2A.
The market is not competitive, but high barrier to entry due to limited clinical validation.
Eph2A Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Eph2A, using small molecule modality.
Explore alternative modalities like antibodies or biologics to differentiate from existing therapies and potentially improve efficacy.
Eph2A Clinical Trials 224 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Eph2A. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 65 | 40 | 10 | 14 | 80% |
| Phase 2 | 127 | 50 | 24 | 53 | 68% |
| Phase 3 | 28 | 13 | 6 | 9 | 68% |
| Phase 4 | 4 | 3 | 1 | 0 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
3 Phase 3 trials testing approved Eph2A drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Eph2A. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Eph2A Drug Approval Timeline (2012 - 2012)
The first and only drug, STIVARGA, was approved in 2012.
The approval timeline indicates a potentially saturated market with limited recent innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 132 (29 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Eph2A. A trial counts if an approved drug acting on Eph2A is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.